Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Meta Compute Launch Sends AI Compute Stocks Tumbling Globally

Meta Compute Launch Sends AI Compute Stocks Tumbling Globally

BeInCryptoBeInCrypto2026/07/02 02:42
By:BeInCrypto
Metas plan to sell surplus computing power hit chip stocks hard on Wall Street. Metas own shares climbed nearly 9% on the news. The announcement flipped years of assumed AI compute scarcity into a supply warning. It erased billions in semiconductor and neocloud value in a single session. A Supply Signal Rattles Wall Street Meta is building a business called Meta Compute. The unit will lease idle data center capacity to outside clients. The approach mirrors SpaceXs model. SpaceX has rented spare capacity to firms including Anthropic. Metas stock price jumped above $600 on the news of Meta Compute. Image Source: Trading View For years, investors rewarded chip suppliers on one premise. They believed AI demand always outstripped supply. Metas admission of excess capacity broke that premise. Recent Nvidia institutional money flow data already show large investors pulling back. Micron sank more than 10% on July 1. SanDisk, Intel and AMD each lost between 6.9% and 10.6%. Nvidia slipped just 1.25%, a modest decline that stood out against the broader rout. Neoclouds and Big Tech Diverge CoreWeave and Nebius rent GPU capacity to AI developers and saw their stocks fall 14% and 17% respectively on fears that Meta will undercut their pricing. Meta has paid for similar cloud services before, but its shift into the same business now puts it in direct competition with its own vendors. Other Magnificent 7 members gained ground. Apple, Microsoft, Amazon, Alphabet and Tesla all closed higher as some strategists link the split to AI spending cycle winners rotating away from pure hardware plays. South Korea Feels the Spillover The sell-off spread to Asia as Samsung and SK Hynix memory stocks fell more than 7% and 9% respectively in early trading and the KOSPI triggered another trading halt. The move extended a pattern from a prior Big Tech selloff spillover that hit Asian chipmakers earlier this year.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales